Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISIS 5132 in Recurrent Epithelial Ovarian Cancer
NCT00003892Phase 2Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Feb 1999
- Primary completion
- Oct 2000
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 3
01
Overview
A Phase 2 trial of isis 5132 in ovarian epithelial cancer, sponsored by Canadian Cancer Trials Group. Started Feb 1999; status: completed.
02
Drugs
isis 5132
03
Conditions
ovarian epithelial cancer
Beyond the preview
Go deeper on NCT00003892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003892.